June 20 An advisory committee for the U.S.
Centers for Disease Control and Prevention on Wednesday voted to
recommended expanded use of Pfizer Inc's Prevnar 13
vaccine to include adults 19 and older with compromised immune
systems due to conditions such as HIV infection, cancer and
advanced kidney disease.
The Advisory Committee on Immunization Practices
(ACIP)favored the expanded use by a vote of 14-0 with one
abstention, the CDC said.
Prevnar 13, one of Pfizer's most important products,
prevents pneumococcal pneumonia or invasive disease. Wall Street
analysts, on average, have forecast Prevnar 13 sales reaching
$6.75 billion by 2016. The company reported sales of $941
million in the first quarter.
Prevnar 13 was initially approved by the U.S. Food and Drug
Administration in 2010 for prevention of invasive pneumococcal
disease caused by the 13 serotypes included in the vaccine in
infants and children from 6 weeks through 5 years old.
The FDA in December approved Prevnar 13 for adults age 50
and older. ACIP has not yet recommended the vaccine for that
"We are committed to continuing discussions with the ACIP
with the aim of expanding the recommendations to include all
adults 50 years of age and older - a population rapidly
increasing in the United States and at risk for developing
vaccine-type pneumococcal pneumonia and invasive disease,"
Pfizer said in a statement.
The vaccine is not approved for those between the ages of 6
Pfizer shares were off 2 cents at $22.69 in midday trading
on the New York Stock Exchange.